Navigation Links
Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
Date:6/2/2009

nt of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
2. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. Pharmasset Reports Fiscal Year End 2008 Financial Results
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
7. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel of ... reacts to a recent study, which shows how grief in ... http://photos.prnewswire.com/prnh/20140723/129709 According to US ... are more likely than others to grow up overweight or ... There were two specific types of stress that caused ...
(Date:7/24/2014)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... conference call to report its second quarter 2014 financial ... and outlook on Thursday, August 7, 2014 at 8:30 ... The call can be accessed by dialing ... prior to the start of the call and providing ...
(Date:7/24/2014)... , Germany , and ... -- , Exclusive global license ... for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, ... to be targeted by new test, indicate favorable prognosis ... syndromes  QIAGEN sees potential for developing companion ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5
... Dec. 5, 2010 Pfizer Inc. (NYSE: ... has elected Ian C. Read, 57, currently head of ... Officer and Director. Mr. Read succeeds Jeffrey B. Kindler, ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) The Board,s Lead Independent Director, ...
... The Infectious Disease Research Institute (IDRI) has ... Advance Research and Development Authority (BARDA). IDRI,s work will ... to $8.5 million over three years when further development ... agency. "BARDA is supporting an important ...
Cached Medicine Technology:Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 2Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 3Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 4IDRI Awarded Contract from BARDA to Develop Next Generation Adjuvants for Pandemic Influenza 2
(Date:7/25/2014)... 25, 2014 This is a ... of the Galactooligosaccharides (GOS) industry in Global ... of the industry, including definitions, applications and industry ... market analysis are provided with a focus on ... market. A comparison between the international and Chinese ...
(Date:7/25/2014)... 25, 2014 Drexel University College of ... MD, MS, FACP, has been appointed vice dean for education, ... Drexel from The Commonwealth Medical College, where she is currently ... clinical affairs, and professor of medicine. , As a ... College, Weber had a major role in many aspects of ...
(Date:7/25/2014)... News) -- Shift workers, especially men, may be at higher ... such schedules, a new study suggests. Also at special ... schedule, with shifts moving around at various times of the ... one expert, Dr. Alan Manevitz, a clinical psychiatrist at Lenox ... known that working shifts disrupts many key body chemicals, creating ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay --, Treatment for lymphoma ... Hodgkin lymphoma and non-Hodgkin lymphoma, which are cancers of ... who are still in their reproductive years. For men, ... production. Although most men regain their fertility within two ... be counseled about the possibility of this significant side ...
(Date:7/25/2014)... new system that sent patients to designated cardiac receiving ... sudden cardiac arrest in Arizona, according to a study ... Medicine . , "We knew lives would be ... guidelines for post-cardiac arrest care and we were able ... to what is done for Level 1 trauma patients," ...
Breaking Medicine News(10 mins):Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 3
... A Georgetown University Medical Center (GUMC) scientist who ... frogs and in the dogfish shark has now turned ... dolphins. A dolphin,s ability to heal quickly from ... to infection, hemorrhage protection, and near-restoration of normal body ...
... and Society of Breast Imaging applaud and support updated ... women begin getting annual mammograms at age 40. The ... American Cancer Society, ACR, Society of Breast Imaging (SBI), ... major medical associations with demonstrated expertise in breast cancer ...
... Reporter , WEDNESDAY, July 20 (HealthDay News) -- High-tech helmets ... the force of impact, offering new insight into head and ... help manufacturers design helmets that are more protective, said Steven ... Michigan and lead author of a new report about the ...
... test to distinguish harmless from precancerous pancreatic cysts. ... surgery to remove the harmless variety. A report ... issue of Science Translational Medicine . The ... than a million patients each year, most of whom ...
... News) --, Liars can control certain facial expressions when facing ... a new study shows. The researchers noted the findings ... the study, scientists randomly asked 60 people to either lie ... of movie tickets from an envelope. While being interviewed, the ...
... researchers have developed a new strategy to improve the development ... are created by introducing four defined genes to an adult ... cell, which can differentiate into many different types of the ... Oct4, Sox2, Klf4 and c-Myc, a combination known as OSKM. ...
Cached Medicine News:Health News:Dolphins' 'remarkable' recovery from injury offers important insights for human healing 2Health News:Dolphins' 'remarkable' recovery from injury offers important insights for human healing 3Health News:ACR, SBI support updated ACOG recommendations that women begin annual mammograms at age 40 2Health News:High-Tech Football Helmets Gauge Force of Collision 2Health News:Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts 2Health News:Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts 3Health News:Scrutinizing Faces Might Catch Liars, Study Finds 2Health News:U of M researchers improve method to create induced pluripotent stem cells 2
Aplio was designed for intuitive operation so you can get the results you are looking for quickly and easily. From customizable measurement packages to an ergonomic platform design, Aplio was built m...
This catheter is intended for ultrasound examination of coronary intravascular pathology ONLY. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Fludeoxyglucose F 18 Injection:, The PETNET SafetyNET: 99% On-Time Delivery of MetaTrace FDG , Largest Cyclotron - Equipped Radiopharmacy Network , 39 MetaTrace FDG producing sites , Customi...
... The AB Holter, a ... system, provides sophisticated,ambulatory ECG analysis ... Windows environment.,Designed to use Windows ... the system allows,the option of ...
Medicine Products: